KHAN WA; THE ZIMBASA DYSENTERY STUDY GROUP; Interscience Conference on Antimicrobial Agents and Chemotherapy (41st : 2001 : Chicago, Ill.).
Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother. 2001 Dec 16-19; 41: abstract no. G-1556.
Intl. Ctr. for Diarrhoeal Disease Res., Bangladesh (ICDDR, B), Dhaka, Bangladesh
BACKGROUND: SD1 is the cause of epidemic dysentery, and a major killer of children in Africa and Asia. Effective short-course antimicrobial therapy has been identified for the treatment of Shigella but not for SD1. METHODS: We compared the efficacy of 6-dose CIP (15 mg/kg q 12 h, maximum 500 mg, x 3 d) with standard 10-dose CIP therapy (same dose q 12h x 5d) in children infected with SD1 and dysentery 6 stools, > 1 watery stool or any bloody mucoid stools. Bacteriologic failure occurred if SD1 could be isolated after study day 2. RESULTS: 132 patients infected with SD1 were enrolled, and 128 were eligible for analysis. Therapy was clinically effective in 43 (65%) of 66 patients on 3d therapy, and 43 (69%) of 62 patients on 5 d therapy (difference 4%, 95% CI 12 to 20%, P = 0.75). Bacteriological efficacy was 100% in both groups. All isolates were susceptible to CIP. There were no signs of arthropathy in any of the patients. CONCLUSION: 3 d CIP was clinically and microbiologically equivalent to 5 d CIP in children with SD1 infection, and should be the treatment of choice for SD1 infections in children.
Publication Types:
Keywords:
- Africa
- Anti-Infective Agents
- Asia
- Blindness
- Child
- Ciprofloxacin
- Clinical Trials as Topic
- Communicable Diseases
- Double-Blind Method
- Dysentery, Bacillary
- Humans
- Infection
- Shigella
- Shigella dysenteriae
- therapy
Other ID:
UI: 102270165
From Meeting Abstracts